>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Methyltransferase>>AMI-1 free acid

AMI-1 free acid

Catalog No.GC39840

AMI-1 유리산은 인간 PRMT1 및 효모-Hmt1p에 대해 각각 8.8μM 및 3.0μM의 IC50을 갖는 단백질 아르기닌 N-메틸트랜스퍼라제(PRMT)의 강력한 세포 투과성 및 가역적 억제제입니다. AMI-1 유리산은 펩타이드-기질 결합을 차단하여 PRMT 억제 효과를 발휘합니다.

Products are for research use only. Not for human use. We do not sell to patients.

AMI-1 free acid Chemical Structure

Cas No.: 134-47-4

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$30.00
재고 있음
5mg
US$27.00
재고 있음
10mg
US$27.00
재고 있음
25mg
US$45.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com


고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

AMI-1 free acid is a potent, cell-permeable and reversible inhibitor of protein arginine N-methyltransferases (PRMTs), with IC50s of 8.8 μM and 3.0 μM for human PRMT1 and yeast-Hmt1p, respectively. AMI-1 free acid exerts PRMTs inhibitory effects by blocking peptide-substrate binding[1].

[1]. Donghang Cheng, et al. Small Molecule Regulators of Protein Arginine Methyltransferases. J Biol Chem. 2004 Jun 4;279(23):23892-9. [2]. Zhang, B., et al. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3. Oncotarget. 2015 Sep 8;6(26):22799-811. [3]. Donghang Cheng, et al. Small Molecule Regulators of Protein Arginine Methyltransferases. J Biol Chem. 2004 Jun 4;279(23):23892-9. [4]. Baolai Zhang, et al. Arginine Methyltransferase inhibitor-1 Inhibits Sarcoma Viability in vitro and in vivo. Oncol Lett. 2018 Aug;16(2):2161-2166.

리뷰

Review for AMI-1 free acid

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AMI-1 free acid

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.